JP2021516996A5 - - Google Patents

Info

Publication number
JP2021516996A5
JP2021516996A5 JP2020571337A JP2020571337A JP2021516996A5 JP 2021516996 A5 JP2021516996 A5 JP 2021516996A5 JP 2020571337 A JP2020571337 A JP 2020571337A JP 2020571337 A JP2020571337 A JP 2020571337A JP 2021516996 A5 JP2021516996 A5 JP 2021516996A5
Authority
JP
Japan
Prior art keywords
human
polypeptide
cells
amino acid
polypeptide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020571337A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021516996A (ja
JP7846963B2 (ja
Filing date
Publication date
Priority claimed from US15/916,689 external-priority patent/US10869887B2/en
Application filed filed Critical
Publication of JP2021516996A publication Critical patent/JP2021516996A/ja
Publication of JP2021516996A5 publication Critical patent/JP2021516996A5/ja
Priority to JP2023204147A priority Critical patent/JP2024037778A/ja
Application granted granted Critical
Publication of JP7846963B2 publication Critical patent/JP7846963B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020571337A 2015-09-11 2019-03-08 生物学的に関連する直交サイトカイン/受容体対 Active JP7846963B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023204147A JP2024037778A (ja) 2015-09-11 2023-12-01 生物学的に関連する直交サイトカイン/受容体対

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562217364P 2015-09-11 2015-09-11
US201662375089P 2016-08-15 2016-08-15
US15/916,689 2018-03-09
US15/916,689 US10869887B2 (en) 2015-09-11 2018-03-09 Biologically relevant orthogonal cytokine/receptor pairs
PCT/US2019/021451 WO2019173773A1 (en) 2015-09-11 2019-03-08 Biologically relevant orthogonal cytokine/receptor pairs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023204147A Division JP2024037778A (ja) 2015-09-11 2023-12-01 生物学的に関連する直交サイトカイン/受容体対

Publications (3)

Publication Number Publication Date
JP2021516996A JP2021516996A (ja) 2021-07-15
JP2021516996A5 true JP2021516996A5 (cg-RX-API-DMAC7.html) 2022-03-16
JP7846963B2 JP7846963B2 (ja) 2026-04-16

Family

ID=58240003

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018513275A Active JP7299021B2 (ja) 2015-09-11 2016-09-07 生体関連の直交性サイトカイン/受容体ペア
JP2020571337A Active JP7846963B2 (ja) 2015-09-11 2019-03-08 生物学的に関連する直交サイトカイン/受容体対
JP2021180486A Active JP7495385B2 (ja) 2015-09-11 2021-11-04 生体関連の直交性サイトカイン/受容体ペア
JP2023204147A Pending JP2024037778A (ja) 2015-09-11 2023-12-01 生物学的に関連する直交サイトカイン/受容体対
JP2024013400A Pending JP2024054175A (ja) 2015-09-11 2024-01-31 生体関連の直交性サイトカイン/受容体ペア

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018513275A Active JP7299021B2 (ja) 2015-09-11 2016-09-07 生体関連の直交性サイトカイン/受容体ペア

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021180486A Active JP7495385B2 (ja) 2015-09-11 2021-11-04 生体関連の直交性サイトカイン/受容体ペア
JP2023204147A Pending JP2024037778A (ja) 2015-09-11 2023-12-01 生物学的に関連する直交サイトカイン/受容体対
JP2024013400A Pending JP2024054175A (ja) 2015-09-11 2024-01-31 生体関連の直交性サイトカイン/受容体ペア

Country Status (17)

Country Link
US (7) US10869887B2 (cg-RX-API-DMAC7.html)
EP (2) EP3347056A4 (cg-RX-API-DMAC7.html)
JP (5) JP7299021B2 (cg-RX-API-DMAC7.html)
KR (3) KR20250004916A (cg-RX-API-DMAC7.html)
CN (4) CN108430518A (cg-RX-API-DMAC7.html)
AR (1) AR114687A1 (cg-RX-API-DMAC7.html)
AU (4) AU2016318621A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020018293A2 (cg-RX-API-DMAC7.html)
CA (2) CA2998393A1 (cg-RX-API-DMAC7.html)
HK (1) HK1258138A1 (cg-RX-API-DMAC7.html)
IL (2) IL277118B2 (cg-RX-API-DMAC7.html)
MX (1) MX428362B (cg-RX-API-DMAC7.html)
PH (1) PH12020551417A1 (cg-RX-API-DMAC7.html)
RU (1) RU2020133171A (cg-RX-API-DMAC7.html)
SG (1) SG11202008780SA (cg-RX-API-DMAC7.html)
WO (2) WO2017044464A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006168B (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7299021B2 (ja) * 2015-09-11 2023-06-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 生体関連の直交性サイトカイン/受容体ペア
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
KR102777151B1 (ko) 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2020131547A1 (en) * 2018-12-19 2020-06-25 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
MX2021011258A (es) * 2019-03-18 2021-12-10 Biontech Cell & Gene Therapies Gmbh Variantes de interleucina-2 (il2) y receptor de interleucina-2 (il2r) para la activacion especifica de celulas efectoras inmunitarias.
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
CN114555634B (zh) * 2019-08-13 2025-01-10 美国安进公司 用于扩增调节性t细胞的白介素-2突变蛋白
WO2021050752A1 (en) * 2019-09-11 2021-03-18 The Board Of Trustees Of The Leland Stanford Junior University Chimeric orthogonal receptor proteins and methods of use
CA3151471A1 (en) * 2019-10-08 2021-04-15 Gesa VOLKERS Modified extracellular domain of granulocyte colony-stimulating factor receptor (g-csfr) and cytokines binding same
US11648296B2 (en) * 2019-12-13 2023-05-16 Synthekine, Inc. IL-2 orthologs and methods of use
IL293978A (en) * 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
KR20220140514A (ko) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 변형된 il-2 폴리펩타이드 및 그의 용도
CN115315273A (zh) * 2020-01-14 2022-11-08 辛德凯因股份有限公司 Il-2直向同源物及其使用方法
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
KR20220131529A (ko) * 2020-01-14 2022-09-28 신테카인, 인크. 변경된 icd stat 신호전달을 갖는 cd122
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
BR112022017656A2 (pt) * 2020-03-05 2022-10-18 Univ Leland Stanford Junior Variantes de il-2 concebidas
JP2023520572A (ja) * 2020-04-06 2023-05-17 シンセカイン インコーポレイテッド オルソゴナルな受容体を発現するようにゲノムが改変されたヒト免疫細胞
WO2021207290A1 (en) * 2020-04-06 2021-10-14 Synthekine, Inc. Engineered immune cells
KR20230060514A (ko) * 2020-09-01 2023-05-04 다케다 야쿠힌 고교 가부시키가이샤 인터루킨-2 뮤테인 및 이의 용도
CN116529257A (zh) * 2020-10-26 2023-08-01 尼普图恩生物科学有限公司 正交il-21受体/细胞因子系统
WO2022093683A1 (en) * 2020-10-26 2022-05-05 Neptune Biosciences Llc Orthogonal il-21 receptor/cytokine systems
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
EP4305054A4 (en) * 2021-03-09 2025-03-19 The Trustees of The University of Pennsylvania SELECTIVE STIMULATION OF T CELLS IN SOLID TUMORS USING ONCOLYTIC VIRAL ADMINISTRATION OF ORTHOGONAL IL-2
US20240182584A1 (en) * 2021-04-02 2024-06-06 The Board Of Trustees Of The Leland Stanford Junior University Bispecific Molecules and Related Compositions and Methods
WO2022213208A1 (en) * 2021-04-07 2022-10-13 Provincial Health Services Authority Modified granulocyte colony-stimulating factor (g-csf) and chimeric cytokine receptors binding same
KR20240034221A (ko) 2021-07-09 2024-03-13 브라이트 피크 테라퓨틱스 아게 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드
EP4370139A4 (en) * 2021-07-14 2025-10-15 Synthekine Inc METHODS AND COMPOSITIONS FOR USE IN CELL THERAPY FOR NEOPLASTIC DISEASE
EP4402161A1 (en) 2021-09-17 2024-07-24 Parker Institute For Cancer Immunotherapy Switch receptors using il-9 signaling domains
PE20242341A1 (es) * 2022-04-04 2024-12-12 Gammadelta Therapeutics Ltd Blindaje genetico novedoso
EP4293040A1 (en) 2022-06-19 2023-12-20 ETH Zurich Cell line for engineering cytokine receptors
CN121013867A (zh) * 2023-06-07 2025-11-25 Fbd生物制品有限公司 工程化的il-7变体及其使用方法
WO2025245495A1 (en) * 2024-05-24 2025-11-27 Cz Biohub Sf, Llc Selective sensitization of cancer cells to elimination by cytotoxic lymphocytes

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
EP1069917A4 (en) * 1998-03-20 2005-02-09 Genzyme Corp NEW COMPLEMENTARY PAIRS OF RECEPTORS / LIGANDS AND ADOPTIVE IMMUNOTHERAPY USING THE SAME
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US7666400B2 (en) 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
US6926898B2 (en) * 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
EP1454138B1 (en) * 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
KR20070003934A (ko) * 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
US20060199250A1 (en) * 2005-03-04 2006-09-07 Huimin Zhao Method for generating a mutant protein which efficiently binds a target molecule
JP2009542592A (ja) 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Il−2媒介性免疫応答の有効性を高める組成物および方法
JP5703020B2 (ja) 2007-08-24 2015-04-15 ノボ ノルディスク ヘルス ケア アーゲー タンパク質を選択的に修飾するための組成物と方法
EP2560994B1 (en) * 2010-04-08 2016-10-12 JN Biosciences LLC Antibodies to cd122
WO2013074916A1 (en) * 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
LT2884999T (lt) * 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
US9434935B2 (en) * 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
EP2968450A4 (en) 2013-03-15 2016-10-26 Angelica Therapeutics Inc MODIFIED TOXINS
SI2997141T1 (sl) 2013-05-13 2023-04-28 Cellectis CD19 specifični himerni antigenski receptor in njegova uporaba
JP6640834B2 (ja) 2014-08-11 2020-02-05 デリニア, インコーポレイテッド 自己免疫疾患の処置のために調節性t細胞を選択的に活性化させる改変il−2変異体
IL304950A (en) * 2015-04-10 2023-10-01 Amgen Inc Interleukin for the expansion of myotonic control T-2 cells
JP7299021B2 (ja) * 2015-09-11 2023-06-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 生体関連の直交性サイトカイン/受容体ペア
CN107746831B (zh) 2017-11-07 2019-04-23 南京北恒生物科技有限公司 具有化疗药物抗性的通用型cart/tcrt细胞及其构建方法

Similar Documents

Publication Publication Date Title
CN110818802B (zh) 一种嵌合t细胞受体star及其应用
RU2020133171A (ru) Биологически значимые ортогональные пары цитокинов/рецепторов
US10725044B2 (en) T cell receptors and immune therapy using the same
CN108603200B (zh) 优化的慢病毒转移载体及其用途
JP6422134B2 (ja) キメラ抗原受容体
US12497453B2 (en) ROR1 specific chimeric antigen receptors and their therapeutic applications
CN107074929B (zh) 嵌合自身抗体受体t细胞的组合物和方法
JP6639233B2 (ja) Mage−a1を認識する高結合活性結合分子
BR112020024246A2 (pt) pelo menos um polinucleotídeo recombinante, célula recombinante, receptor de antígeno quimérico, polinucleotídeo que codifica o receptor de antígeno quimérico, vetor, vírus, composição farmacêutica, e, método para tratar câncer
JP6985934B2 (ja) 操作された造血幹細胞/前駆細胞及び非tエフェクター細胞、ならびにその使用
JP2017530724A (ja) 多様な多重抗原のターゲティングのための汎用的キメラ抗原受容体を発現する免疫細胞および該免疫細胞の製造方法ならびに該免疫細胞の、癌、感染症および自己免疫疾患の治療のための使用
AU2019370618C1 (en) Bispecific polypeptides for engagement of CAR expressing immune cells with antigen presenting cells and uses thereof
US20060263334A1 (en) Therapeutic and diagnostic cloned MHC-unrestricted receptor specific for the MUC1 tumor associated antigen
JP7606510B2 (ja) Ebv-由来抗原に特異的なtcr構築物
CN115315270A (zh) 工程化免疫细胞
AU2019406447A1 (en) CD22-specific T cell receptors and adoptive T cell therapy for treatment of B cell malignancies
JP7429462B2 (ja) Ssx2抗原の短いペプチドを識別するt細胞受容体
JP2023529416A (ja) キメラ抗原受容体細胞
HK40049020A (en) Bispecific polypeptides for engagement of car expressing immune cells with antigen presenting cells and uses thereof
CN115725504A (zh) 工程化免疫细胞及其用途
CN118574843A (zh) 以可检测的亲和力结合特异性肽的抗原识别构建体和对kras具有抗原特异性的t细胞受体以及相应的核酸序列、载体、宿主细胞、药物组合物和试剂盒
Powell Jr et al. Genetically Engineered Antigen Specificity in T Cells for Adoptive Immunotherapy
BR112016020518B1 (pt) Receptor antigênico quimérico